RXST reported second-quarter 2026 results for RxSight, Inc. with revenue of $33.7 million, slightly above the consensus estimate of $33.2 million. Gross profit came in at $25.9 million, while the company posted an operating loss of $13.8 million and a net loss attributable to common shareholders of $12.1 million.
The company’s loss per share was $0.29, better than the expected $0.34. Operating cash flow remained negative at $9.5 million, and capital spending totaled $2.0 million. Cash and cash equivalents stood at $13.4 million, while total liabilities rose to $89.4 million.
- Revenue increased modestly year over year.
- Gross profit also improved from a year earlier.
- Operating and net losses continued, but the bottom line was stronger than expected.
- Shares fell 4.61% after the market close.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
RxSight, Inc. Hedge Fund Activity
We have seen 86 institutional investors add shares of RxSight, Inc. stock to their portfolio, and 76 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND added 1,000,000 shares (+761.0%) to their portfolio in Q1 2026, for an estimated $6,160,000
- JACOBS LEVY EQUITY MANAGEMENT, INC added 881,200 shares (+476.0%) to their portfolio in Q1 2026, for an estimated $5,428,192
- BNP PARIBAS FINANCIAL MARKETS removed 670,956 shares (-68.8%) from their portfolio in Q1 2026, for an estimated $4,133,088
- FEDERATED HERMES, INC. added 655,063 shares (+153.9%) to their portfolio in Q1 2026, for an estimated $4,035,188
- ACADIAN ASSET MANAGEMENT LLC added 602,299 shares (+144.5%) to their portfolio in Q1 2026, for an estimated $3,710,161
- AQR CAPITAL MANAGEMENT LLC added 537,009 shares (+541.8%) to their portfolio in Q1 2026, for an estimated $3,307,975
- TWO SIGMA INVESTMENTS, LP added 501,901 shares (+62.9%) to their portfolio in Q1 2026, for an estimated $3,091,710
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
RxSight, Inc. Price Targets
Multiple analysts have issued price targets for $RXST recently. We have seen 6 analysts offer price targets for $RXST in the last 6 months, with a median target of $9.0.
Here are some recent targets:
- David Saxon from Needham set a target price of $11.0 on 07/07/2026
- Craig Bijou from B of A Securities set a target price of $6.5 on 07/07/2026
- Larry Biegelsen from Wells Fargo set a target price of $9.0 on 05/07/2026
- Tom Stephan from Stifel set a target price of $9.0 on 03/09/2026
- Adam Maeder from Piper Sandler set a target price of $10.0 on 02/26/2026
- Danielle Antalffy from UBS set a target price of $9.0 on 02/26/2026
